A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
Eisai Inc.
Eisai Inc.
AstraZeneca
H. Lee Moffitt Cancer Center and Research Institute
Pfizer
University of Virginia
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Providence Health & Services
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
University of California, San Diego
Sichuan Enray Pharmaceutical Sciences Company
Ohio State University Comprehensive Cancer Center
Menarini Group
Boehringer Ingelheim
Pfizer
Thomas Jefferson University
Health Hope Pharma
Boehringer Ingelheim
Boehringer Ingelheim
Dana-Farber Cancer Institute
Daiichi Sankyo
NantBioScience, Inc.
Tesaro, Inc.
Vanderbilt-Ingram Cancer Center
Pfizer
Hoffmann-La Roche
Hutchmed
Pfizer
University of Washington
Pfizer
GlaxoSmithKline
Pfizer
Genentech, Inc.
Avera McKennan Hospital & University Health Center
Pfizer
National Cancer Institute (NCI)
ADC Therapeutics S.A.
Merck Sharp & Dohme LLC
Washington University School of Medicine
Amgen
Eli Lilly and Company
Eisai Inc.
EVIVE Biotechnology
Pfizer
Hoffmann-La Roche
Duke University